New FDA commissioner Robert Califf said Wednesday that the recent spike in drug approvals is no temporary phenomenon, thanks to a better understanding of biology and continued adoption of sophisticated technology throughout healthcare.
“I predict we’ll see of a flood of... Read more »
Schizophrenia affects millions of people around the world, which is why any prospective treatment that advances garners close attention. Minerva Neurosciences jumped into the spotlight this morning when an experimental schizophrenia drug it’s developing showed some promise in a mid-stage trial,... Read more »
Usually when a biotech company makes a large fundraising announcement, the cash is committed to taking a specific drug through clinical trials. Arrivo BioVentures has secured $49 million in capital to first find the drugs to develop.
The approach is similar... Read more »
Seismic is making some waves today.
The suburban San Diego software company, which specializes in “sales enablement” and content management software for big companies and organizations, says it has raised $40 million in a Series C funding round led by General... Read more »
The multi-year saga of eteplirsen, a Duchenne muscular dystrophy drug from Cambridge, MA-based Sarepta Therapeutics, will continue to drag on.
Sarepta (NASDAQ: SRPT) said today that the FDA won’t complete its review of its drug, eteplirsen, by the established May... Read more »
Can a concert in a virtual auditorium sell out? To get the best seat, does your avatar have to camp out overnight at the virtual ticket booth?
The questions that come up as virtual reality works its way into the real... Read more »
Selecta Biosciences became a candidate to go public when a group of crossover investors—institutions that back both public and private companies—piled $38 million into the company in September. Nine months later, the Watertown, MA-based company is ready to take the... Read more »
Make the most of the days to come while ignoring a few rules along the way was some of the advice Steve Blank shared Monday in a commencement speech for this year’s graduates at NYU Tandon School of Engineering.
Known for his methodologies... Read more »
Back in 2012, Acorda Therapeutics bought a Morrisville, NC, company called Neuronex as part of a plan to branch out beyond its flagship multiple sclerosis drug dalfampridine (Ampyra). Unfortunately, the drug, a nasal spray form of the old seizure control drug... Read more »
A quick housekeeping note: Starting this week, we are combining our East Coast and West Coast biotech roundups into a single weekly post that will also include highlights from our other cities and regions, including Texas, Michigan, Wisconsin, and Xconomy’s latest... Read more »